



## About the EFPIA Disclosure Code



## Securing the future of collaboration between industry and healthcare professionals

\* Collaboration between industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) benefits patients. It is a relationship that has delivered numerous innovative medicines and changed the way many diseases impact on our lives.

There are numerous examples.

- \* Take HIV, seen as a death sentence in 1980's, is now viewed as a chronic condition that can be managed through the use of innovative medicines.
- \* In cancer, death rates have fallen by 20% since the 1990's in some countries.
- \* Recent pharmaceutical innovation means around 90% of patients living with Hepatitis C can be cured through a 12-week course of medicine.

\* Industry and HCPs collaborate on a range of activities from clinical research, sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. EFPIA believes HCPs should be fairly compensated for the legitimate expertise and services they provide to the industry.

\* Bringing greater transparency to this, already well-regulated and vital relationship builds understanding of industry-HCP/HCO collaboration and, in the context of increasing societal expectations on transparency, addresses directly public concerns about interactions between the medical community and the pharmaceutical industry.

\* That is why, by 30 June 2016, companies will begin disclosing transfers of value made to HCPs, such as consultancy and advisory boards, speaker fees, and sponsorship to attend meetings. This transformational step in the relationship between industry and health professionals is a result of the EFPIA Disclosure Code.



## About the EFPIA Disclosure Code

\* The EFPIA Disclosure Code is a code of conduct that requires all EFPIA member companies and companies that are members of EFPIA member associations to disclose transfers of value to HCPs and HCOs. Under the Code, EFPIA member companies will have to disclose the names of HCPs and HCOs that have received payments or other transfers of value from them. They will also have to disclose – by HCP or HCO – the total amounts of value transferred, by type of activity, which could consist of, for instance, a grant to an HCO, a consultancy fee for speaking, payment for travel, or registration fees to attend a medical education congress.

\* The first disclosures will be made by 30 June 2016, for payments made in 2015. This information will be published on a public platform, which could be on the company's own website or, in some countries, a central platform, combining data from different companies.



## Why was the EFPIA Disclosure Code created?

\* Collaborative working between HCPs and commercial life sciences organisations has long been a positive driver for advancements in patient care and the progression of innovative medicine. Both parties regularly join together, during early scientific research, clinical trials and medical education, in the interests of delivering and advancing high quality patient care. What's more, as the primary point of contact with patients, the medical profession can offer invaluable and expert knowledge on patient outcomes and the management of diseases. This plays a big part in informing the pharmaceutical industry's efforts to improve patient care and treatment options – and is essential in improving health outcomes. A healthy working relationship between the pharmaceutical industry and HCPs/HCOs is in the best interest of patients. The EFPIA Disclosure Code was created to protect the integrity of these relationships, and represents a step towards fostering greater transparency and building greater trust between the pharmaceutical industry, the medical community and society across Europe.

## Who needs to comply with the EFPIA Disclosure Code?

\* The EFPIA General Assembly formally adopted the EFPIA Disclosure Code on June 24, 2013. The Code applies to all EFPIA members including: Corporate Member Companies; Members of EFPIA Specialised Groups: (i) European Bio-pharmaceutical Enterprises (EBE) and Vaccines Europe (VE); and Member Companies of Member Associations that are not directly members of EFPIA. This includes most major pharmaceutical companies operating in Europe. You can find a list of EFPIA Member Companies, Member Associations and the countries they operate in, at: [www.efpia.eu/about-us/membership](http://www.efpia.eu/about-us/membership).

## Where do I find out more information?

\* You can access more information at [www.efpia.eu/disclosure](http://www.efpia.eu/disclosure).



EFPIA Brussels Office  
Leopold Plaza Building \* Rue du Trône 108  
B-1050 Brussels \* Belgium  
Tel: + 32 (0)2 626 25 55  
[www.efpia.eu](http://www.efpia.eu) \* [info@efpia.eu](mailto:info@efpia.eu)

